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Summary
PRINCIPLES: In-hospital care of patients with
community-acquired pneumonia (CAP) varies across hos-
pitals. Understanding of the underlying factors is the basis
for tailored quality improvements. Using data from a ran-
domised controlled Swiss-wide multicentre trial, we com-
pared length of stay (LOS) and other patient outcomes
according to (A) the use of a procalcitonin (PCT)-based
antibiotic stewardship protocol, (B) institution type (uni-
versity vs non-university), and (C) historical time period
in relation to the introduction of Diagnosis Related Group
(DRG) reimbursement (2012).
Abbreviations
ARDS acute respiratory distress syndrome
CAP community-acquired pneumonia
CI confidence interval
COPD chronic obstructive pulmonary disease
CRP C-reactive protein
DRG Diagnosis Related Group
HR hazard ratio
IQR interquartile range
LOS length of stay
OR odds ratio
PCT procalcitonin
PPS prospective payment system
PSI Pneumonia Severity Index
SD standard deviation
METHODS: We included 784 patients hospitalised with
CAP from six institutions into this secondary analysis. We
used multivariable regression models adjusted for age, co-
morbidities and disease severity to determine the influence
of institution characteristics on LOS and patient outcomes.
FINDINGS: LOS was significantly shorter in the insti-
tution using a PCT-based antibiotic stewardship protocol
(9.2 vs 5.3 days; adjusted mean difference 3.92 days; 95%
confidence interval [CI] 5.16–2.68) with shorter antibiotic
treatment. There was no difference in LOS in university
vs non-university hospitals, but antibiotic courses in
university-type hospitals were longer (11.0 vs 8.3 days; ad-
justed mean difference 2.59 days; 95% CI, 1.69–3.49). No
significant difference in LOS was found when comparing
the time period before and after the introduction of the
DRG system in Switzerland.
CONCLUSIONS: We found differences in LOS associated
with theuse of a PCT-based antibiotic stewardship protocol,
which remained robust after multivariable adjustment. Im-
portantly, the type of institution and model of reimburse-
ment did not influence LOS in our CAP cohort. More
health services research studies are needed to establish
causal effects.
Key words: community-acquired pneumonia; length of
stay; quality of care; practice guidelines; treatment
protocol; hospital type; reimbursement system
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Introduction
Healthcare expenses are rising in Switzerland, as in many
other countries in Europe and worldwide. During recent
years the level of healthcare costs in Switzerland increased
although the rate at which costs increased slowed during
the 15-year period from 1996 to 2011. Between 2006 and
2011, total health-related costs increased at an average an-
nual rate of about 2.1%, attaining about 65 billion Swiss
francs in 2011 [1]. Identifying possible inefficiencies and
understanding the underlying sources is thus a core issue
of healthcare management to improve the performance of
hospitals. Importantly, studies about efficiency of hospitals
should focus not only on economic outcome but also on
clinical outcome. To assess quality of care, measures such
as time to clinical stability and return to daily activity,
or low rates of complications and mortality are key com-
parators. Common diseases with a large economic burden
are ideal targets for quality improvement initiatives [2, 3].
In this context, community-acquired pneumonia (CAP) is
an important disease affecting 1.6 to 11 per 1000 adults
[4–6]. It is still one of the most common acute infections
necessitating hospitalisation [7, 8] and it is, according to
the World Health Organization, the fourth leading cause
of death worldwide and accounts for the leading cause of
disability-adjusted life years (DALYs) [9–11]. Rates of in-
hospital care for CAP range between 15% and 60%. Im-
portantly, costs for in-hospital care are high and closely re-
lated to length of hospital stay (LOS) [12–15].
The variability among hospitals in quality of care in gen-
eral, and LOS in particular, has many influencing factors
[2, 13, 16]. Three main categories may explain this variab-
ility including (1) patients’ characteristics (mainly severity
of disease and comorbidities), (2) physicians’ practices and
skills, as well as adherence to guidelines for the treatment
of CAP [5, 17], and (3) hospital or healthcare system-re-
lated characteristics [18]. As patient characteristics cannot
directly be influenced, interventions should focus on im-
provement either of physicians’ skills or of hospital pro-
cesses including in-hospital and discharge management,
respectively. Implementation of clinical pathways and pre-
diction rules to standardise care and to facilitate daily work
are effective in improving LOS and clinical outcomes
[19–21]. The Pneumonia Severity Index (PSI), which strat-
ifies the patients into five categories of risk for 30-day mor-
tality, may help with severity adjustment, triage and im-
proving site-of-care decisions upon emergency department
presentation [22, 23]. Similarly, antibiotic stewardship pro-
tocols including procalcitonin (PCT) have been found to
markedly lower antibiotic consumption and improve care
of CAP patients, with positive effects on antibiotic-related
side effects and on mortality in the context of critically-ill
patients [24–27]. Although PCT has been found effective
in safely reducing use and duration of antibiotic treatment,
there is insufficient evidence of its real-life impact on rel-
evant social and economic variables such as healthcare-re-
lated costs or LOS [28, 29].
Hospital-related characteristics, such as the size or type of a
hospital (university vs non-university hospitals), may also
influence quality of care and LOS even more than a single
procedure such as the implementation of a clinical treat-
ment protocol [2, 13, 16, 20]. The effects may partly relate
to patient characteristics as sicker patients tend to be hos-
pitalized to larger public hospitals, but other effects may
also exist, and further research to highlight these factors is
still in demand.
The reimbursement system may also affect quality of care
and influence LOS [30, 31]. In Switzerland, the Swiss
Parliament passed a law to introduce a Diagnosis Related
Group (DRG)-based hospital financing system, replacing
various fee-for-service financing systems in the different
cantons (states) on 1 January 2012. The DRG system was
expected to create an incentive for hospitals to perform
medical care as cheaply as possible, and thus reduce pa-
tients’ LOS and thereby curtail the increasing costs asso-
ciated with in-hospital patient care. Whether the quality of
care will be affected by the transition of the reimbursement
system remains, however, unclear [32–34].
Having access to the database of a large and well-conduc-
ted multicentre randomised study in CAP [35], we had a
unique opportunity to compare quality of care and patient
outcomes in hospital based on (A) the use of a PCT-based
antibiotic stewardship protocol, (B) institution type (uni-
versity vs non-university) and (C) historical time period in
relation to the introduction of DRG-based reimbursement
(2012).
Methods
Aims
The aim of this analysis was to investigate differences in
quality of care, defined as LOS, time to clinical stability,
duration of antibiotic treatment, and adverse patient out-
comes across hospitals based on three institution charac-
teristics, namely (A) use of a PCT-based antibiotic stew-
ardship protocol, (B) type of institution (university vs non-
university) and (C) historical time period in relation to the
introduction of DRG reimbursement (1 January 2012).
Study design, setting and patients
This was a secondary analysis of an investigator-initiated,
multicentre, randomised, placebo-controlled trial with the
primary outcome of time to clinical stability in CAP pa-
tients treated with adjunct corticosteroids or placebo [35].
The conduct of the original trial adhered to the declaration
of Helsinki and good clinical research practice guidelines,
and ethics committees of all participating hospitals ap-
proved the study prior to patient recruitment. All patients
provided written informed consent. A detailed study pro-
tocol has been published previously (ClinicalTrials.gov.
number NCT00973154) [36].
In brief, from December 2009 to May 2014, from a total
of 2911 potential patients, 802 patients presenting with the
diagnosis of a lower respiratory tract infection were con-
secutively enrolled at emergency departments or medical
wards in seven different hospitals in Switzerland, and un-
derwent randomisation. After blinded post-randomisation
exclusion of 17 patients retrospectively not meeting eligib-
ility criteria, 392 patients were allocated to adjunct pred-
nisone treatment and 393 patients to placebo.
Original article Swiss Med Wkly. 2016;146:w14337
Swiss Medical Weekly · PDF of the online version · www.smw.ch Page 2 of 10
Inclusion criteria were age of 18 years or older and hospit-
alisation with CAP defined as a new infiltrate on chest ra-
diograph and the presence of at least one of the following
signs and symptoms: cough, sputum production, dyspnoea,
core body temperature ≥38.0 °C, auscultatory findings of
abnormal breathing sounds or rales, leukocyte count >10.0
or <4.0 G/l [37]. Exclusion criteria were permanent inabil-
ity to give informed consent, active intravenous drug use,
acute burn injury, gastrointestinal bleeding within the past
3 months, known adrenal insufficiency, a condition requir-
ing more than 0.5 mg/kg/d prednisone or equivalent, preg-
nancy or breast feeding, and severe immunosuppression
Severe immunosuppression was defined as one of the fol-
lowing: infection with human immunodeficiency virus and
a CD4 cell count below 350 G/l, immunosuppressive ther-
apy after solid organ transplantation, neutropenia <0.5 G/l
or neutrophils of 0.5–1 G/l during ongoing chemotherapy
with an expected decrease to values below 0.5 G/l, cyst-
ic fibrosis, or active tuberculosis [35]. The aim of the ini-
tial study was to evaluate whether short-term corticosteroid
treatment reduces time to clinical stability in patients hos-
pitalised for CAP.
All patients were treated according to current CAP
guidelines [38, 39]. Within the study, the decision of the
type and duration of intravenous or total antibiotic treat-
ment, as well as the decision to discharge patients, was left
to the discretion of the treating physicians without interfer-
ence by the study team. However, all of the treating phys-
icians had access to the study flow chart, which suggested
objective discharge criteria (possible oral intake of food,
liquids and drugs, stable vital signs >24 hours, recovery
from CAP-related worsening of mental status, no evidence
of acute serious CAP or related comorbidity that necessit-
ated further hospitalisation).
Patient outcomes
Baseline data contained medical history items, relevant co-
morbidities, clinical items relating to pneumonia, and all
parameters required for the calculation of the PSI [22].
Study nurses evaluated patients every 12 hours during hos-
pitalisation for clinical stability (primary endpoint in the
original study). Clinical stability was defined as time (days)
until stable vital signs (including temperature of 37.8 °C or
lower, heart rate of 100 beats per minute or lower, spontan-
eous respiratory rate of 24 breaths per min or lower, systol-
ic blood pressure of 90 mm Hg or higher, mental status
back to level, ability to intake orally, and adequate oxygen-
ation on room air) for 24 hours or longer [35]. In addition,
duration of total and intravenous antibiotic treatment was
recorded, as was time to discharge from hospital, all-cause
mortality and incidence of CAP complications (i.e. acute
respiratory distress syndrome [ARDS], empyema, persist-
ence of pneumonia) within 30 days. Structured follow-
up telephone interviews for secondary outcomes after dis-
charge were performed on day 30 and included assessment
of adverse events such as recurrence of pneumonia, or re-
hospitalisation.
In this secondary analysis we examined quality of care
and patient outcomes defined as follows: length of stay
(LOS: time from hospitalisation to effective hospital dis-
charge measured in days) as our main endpoint; time to
clinical stability (as defined in the initial trial), total dur-
ation and duration of intravenous antibiotic treatment (de-
tails on dosing of all prescribed antimicrobials during the
study period were recorded by study nurses and reassessed
every 12 hours), death from any cause within 30 days, re-
hospitalisation and CAP complications such as ARDS, em-
pyema, persistence of pneumonia, as well as respiratory
failure or CAP-associated mortality, which was defined as
death from CAP or CAP complications, until day 30 as fur-
ther endpoints.
Statistical analysis
We used descriptive statistics including means and standard
deviations (SDs), medians and interquartile ranges (IQRs;
25th–75th percentiles), or natural frequencies and percent-
ages to summarise data. Two-group comparison was done
by chi-square tests and the student’s t test or Mann-Whit-
ney U test as appropriate. Our main research question was
to compare quality of care and patient outcomes according
to three institution characteristics: (A) use of a PCT-based
antibiotic stewardship protocol, (B) type of institution (uni-
versity vs non-university) and (C) historical time period in
relation to the introduction of DRG reimbursement. Ac-
cordingly, we performed three separate statistical analyses
using univariable and multivariable regression analysis.
For our first analysis (A), we compared one centre that had
the PCT stewardship algorithm routinely implemented, and
continuously promoted its use (PCT-enforced) to all oth-
er centres, in which the algorithm was not promoted in the
same manner (non-PCT-enforced). For the second analysis
(B), we divided the institutions based on the characterisa-
tion made by the Federal Statistical Office and the Feder-
al Office of Public Health into university type (K111) and
non-university type (K112) [40]. One hospital did not meet
either definition, and was thus excluded (characterised as a
basic hospital, K121). The above-mentioned PCT-enforced
centre was secondarily excluded although it met the defin-
ition of a type K112 hospital. For the third analysis (C),
we compared patients included up to December 2011 with
patients enrolled from 1 January 2012 until the end of the
study in May 2014. The cantons of two of the involved hos-
pitals (Aargau and Solothurn) introduced an AP-DRG re-
imbursement system based on the German G-DRG system
before SwissDRG was implemented nationwide in 2012.
These two hospitals were excluded from that analysis.
For all outcomes, unadjusted and adjusted effect estimates
were calculated together with corresponding 95% confid-
ence intervals (CIs) using linear, logistic, or Cox propor-
tional hazards regression (as appropriate). Regression mod-
els were adjusted for the following possible predefined
confounders: Total PSI, maximum level of C-reactive pro-
tein (CRP), age, initial randomisation, current smoking
status, and presence of chronic obstructive pulmonary dis-
ease (COPD), diabetes mellitus, cerebrovascular disease,
congestive heart failure, malignancy or renal insufficiency.
In the third analysis investigating the influence of the re-
imbursement system we additionally adjusted for the treat-
ing centre because some centres joined the trial late and
recruitment was thus uneven in the different centres over
time. The variables for multivariable adjustment were pre-
planned on the basis of biological plausibility and the cur-
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rent literature [2, 41, 42]. We also performed several sens-
itivity analyses additionally adjusting for time to clinical
stability and presence of bacteraemia.
All statistical tests were two-sided and carried out at a
significance level of 5%. Analyses were performed with
STATA 12.1 (Stata Corp, College Station, Texas, USA).
Results
Baseline characteristics
This secondary analysis included 784 patients with a def-
inite diagnosis of CAP, whose data were collected during
the original study from December 2009 to May 2014. The
mean age of the patients was 69.8 years, and 38% were wo-
men. Patients had a high burden of comorbidities including
diabetes, congestive heart failure, COPD and chronic ren-
al insufficiency. The majority of patients were in high-risk
PSI classes IV and V.
Baseline characteristics of the population overall and strat-
ified by (A) the use of a PCT-based antibiotic stewardship
protocol (PCT-enforced centre vs non-PCT-enforced
centres), (B) the type of institution (university vs non-uni-
versity) and (C) historical time period in relation to the in-
troduction of the DRG reimbursement are shown in table 1.
For our first analysis (A), patient characteristics in terms
of age and gender were similar, as were most baseline data
except for neoplastic disease (10.8% vs 6.0%), history of
chills (28.4% vs 43.6%), body temperature (37.4 °C vs 37.7
°C), and creatinine levels (114.3 µmol/l vs 101.0 µmol/l).
For the analysis according the type of institution (B) we
had an older population in university hospitals. Also, there
were significantly more patients with congestive heart fail-
ure and renal failure in university hospitals. Total PSI score
in university hospitals was higher than in non-university
hospitals (94.9 points vs 86.2 points) and we had signific-
antly more patients in higher PSI classes in university hos-
pitals than in non-university hospitals. Further, there were
differences in clinical signs and laboratory findings such as
a history of chills, mean body temperature, and CRP and
albumin levels.
In the third analysis (C), the patient population in the time
before implementation of DRGs had fewer current smokers
(20.3% vs 27.9%) but more chronic renal failure (35.3% vs
27.1%) compared with the time after the implementation of
DRGs.
Differences in quality of care
In our first analysis (A) comparing the PCT-enforced centre
to non-PCT-enforced centres, mean LOS was significantly
shorter in the PCT-enforced centre (5.3 vs 9.2 days, mean
difference 3.92 days, 95% CI 2.6-5.24, p <0.001). This res-
ult was confirmed in multivariate linear regression models
(mean difference [MD] 3.92, 95% CI 5.16–2.68) adjusted
for age, initial randomisation, severity (PSI score) and co-
morbidities. We also performed a sensitivity analysis ad-
ditionally adjusting for time to stability and bacteraemia
(see appendix), which showed robust results. Median time
to clinical stability (3.0 vs 4.0 days; adjusted hazard ratio
[HR] 1.41, 95% CI 1.16–1.70, p <0.001), total duration
of antibiotic treatment (MD –1.85 days, 95% CI –2.77 to
–0.95, p <0.001), and intravenous antibiotic treatment (MD
–2.10 days, 95% CI –2.96 to –1.25, p <0.001) were all sig-
nificantly shorter in the PCT-enforced centre. There was
a significant difference in 30-day mortality in the univari-
ate analysis (6.76% vs 2.99%, p = 0.033), which was no
longer significant after multivariable adjustment (adjusted
odds ratio [OR] 2.07, 95% CI 0.84–5.08, p = 0.113). There
was no difference in adverse outcomes such as rehospital-
isation (adjusted OR 0.52, 95% CI 0.23–1.2, p = 0.127),
or CAP-associated complications (2.7% vs 4.56%; adjusted
OR 0.64, 95% CI 0.21–1.93, p = 0.428). Detailed results
are shown in table 2.
As shown in table 3, the second analysis (B) with regard
to type of hospital did not reveal a significant difference
between LOS in university hospitals and non-university
hospitals (mean LOS 9.9 vs 7.8 days; MD –1.22 days, 95%
CI –0.06 to 2.51, p = 0.061). On the other hand, total dur-
ation of antibiotics (11.0 vs 8.3 days; MD 2.59 days, 95%
CI 1.69–3.49, p <0.001), and intravenous antibiotic treat-
ment (6.6 vs 4.9 days; MD 1.35 days, 95% CI 0.46–2.23,
p = 0.003) were significantly longer in university hospitals.
These significant findings were confirmed in adjusted re-
gression analyses. Because time to clinical stability was
significantly different in university hospitals compared
with non-university hospitals (4.42 vs 2.5 days), we per-
formed a sensitivity analysis adjusted for time to clinical
stability. After full adjustment there was no longer any sig-
nificant difference in the duration of intravenous antibiot-
ic treatment, but the significance in total duration of an-
tibiotics remained robust (appendix, supplementary table
S1). CAP-associated complications were lower in non-uni-
versity hospitals (5.79% vs 1.55%; adjusted OR 3.66, 95%
CI 1.06–12.71, p = 0.041). There was no difference in ad-
verse advents such as rehospitalisation (adjusted OR 1.27,
95% CI 0.63–2.56, p = 0.501), or death within 30 days (ad-
justed OR 5.54, 95% CI 0.7–43.9, p = 0.105).
Table 4 shows results of the third analysis (C) comparing
outcomes in regard to DRG implementation. There was no
significant difference in LOS (mean LOS 9.7 vs 8.8 days;
adjusted MD 0.69 days, 95% CI 1.92 to –0.54, p = 0.271)
before and after DRG implementation. Also, there was no
significant difference in time to clinical stability or use of
antibiotics between the two groups. Death from any cause
within 30 days or rehospitalisation were similar before and
after the implementation of DRGs. CAP-associated com-
plications tended to be lower after the implementation of
the DRG reimbursement system (6.1% vs 3.03%; adjusted
OR 0.34, 95% CI 0.13–0.91, p = 0.032).
Sensitivity analysis
We also performed sensitivity analyses, adjusting the mod-
els for additional parameters. Adjusting the models for
ARDS and ICU admission did not affect the analysis, par-
ticularly for LOS. Also, inclusion of mortality into the
model did not change the outcomes estimates. Models also
remained mostly robust when adding time to clinical sta-
bility and bacteraemia with the exception of the duration of
intravenous antibiotic treatment in analysis B as mentioned
above, and of CAP-associated complications in analysis B
that were no longer significantly differing when adjusting
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as well for time to clinical stability and bacteraemia (sup-
plementary table S1).
Discussion
In this secondary analysis of a previous randomised con-
trolled trial, we assessed LOS and adverse patient out-
comes across different Swiss hospitals in regard to use
of a PCT-based antibiotic stewardship protocol, type of
hospital, and time period before and after DRG imple-
mentation. Because of possible differences in patient pop-
ulations across these institutions, multivariable adjustment
was made. The study revealed three key findings. First,
the centre using a PCT-based antibiotic stewardship pro-
tocol had a significantly reduced LOS of 3.9 days and a
shorter duration of antibiotic treatment of about 2 days
with otherwise similar patient outcomes. Second, patients
in university-type hospitals had longer antibiotic courses
and more CAP-related complications, but the type of the
institution did not influence LOS. Third, in our cohort
of CAP patients DRG implementation did not affect any
measures of outcome in the observed time period.
Implementation of biomarker-based treatment protocols –
if well-conceived and implemented – facilitates daily work
and is effective in improving LOS and clinical outcomes
[19–21]. Efficacy, practicability and safety of a PCT-
guided antibiotic stewardship protocol have been investig-
ated in several randomised controlled trials although LOS
was not reduced in these studies [25, 43–46]. Also, real-
life studies found favourable outcomes when the PCT al-
gorithm was used outside of trial conditions [47, 48]. Our
results are in line with these findings and show a lower use
of resources in regard to antibiotic treatment and LOS with
similar patient outcomes in the centre enforcing a PCT-
Table 1: Baseline characteristics of patients according to: (A) use of antibiotic stewardship protocol including procalcitonin; (B) type of institution (university vs non-
university); (C) historical time period in relation to the introduction of DRG reimbursement.
A B C
Characteristic All patients
(n = 784)
PCT-enforced
centre
(n = 148)
Non-PCT-
enforced
centres
(n = 636)
p-
value
University
hospitals
(n = 432)
Non-
university
hospitals
(n = 341) *
p-
value
Before
Implementation
of DRG
(n = 295)†
After
Implementation
of DRG
(n = 330)†
p-
value
Demographics
Age (years) 69.8 (17.1) 70.2 (18.2) 69.6 (16.8) 0.7 70.7 (16.6) 67.2 (16.8) 0.0017 69.15 (17.8) 70.1 (15.8) 0.45
Female Sex 298 (38.0%) 58 (39.2%) 239 (37.6%) 0.72 151 (35.0%) 83 (43.0%) 0.055 112 (38.0%) 122 (37.0%) 0.8
Previous history
Current smoker 201 (25.6%) 45 (30.4%) 156 (24.5%) 0.14 104 (24.1%) 48 (24.9%) 0.83 60 (20.3%) 92 (27.9%) 0.028
Body mass index
(kg/m2)
26.6 (6.3) 27.0 (5.4) 26.5 (6.5) 0.4 26.6 (6.9) 26.4 (5.6) 0.68 26.7 (5.7) 26.4 (7.2) 0.54
Coexisting Illnesses
Diabetes 155 (19.8%) 28 (18.9%) 127 (20.0%) 0.77 94 (21.8%) 32 (16.6%) 0.13 61 (20.7%) 65 (19.8%) 0.77
Heart failure 142 (18.1%) 28 (18.9%) 114 (18.0%) 0.78 90 (20.9%) 23 (11.9%) 0.007 55 (18.6%) 58 (17.6%) 0.74
COPD 136 (17.3%) 26 (17.6%) 110 (17.3%) 0.94 81 (18.8%) 26 (13.5%) 0.11 50 (16.9%) 57 (17.3%) 0.91
Cerebrovascular
disease
69 (8.8%) 15 (10.1%) 54 (8.5%) 0.53 41 (9.5%) 11 (5.7%) 0.11 23 (7.8%) 29 (8.8%) 0.65
Renal failure 251 (32.0%) 52 (35.1%) 199 (31.3%) 0.37 149 (34.6%) 44 (22.8%) 0.003 104 (35.3%) 89 (27.1%) 0.027
Neoplastic disease 54 (6.9%) 16 (10.8%) 38 (6.0%) 0.037 28 (6.5%) 10 (5.2%) 0.53 21 (7.1%) 17 (5.2%) 0.31
Clinical history and findings
History of chills 319 (40.6%) 42 (28.4%) 277 (43.6%) <0.001 207 (47.9%) 68 (35.2%) 0.003 141 (47.8%) 134 (40.6%) 0.071
History of cough 662 (84.3%) 129 (87.2%) 532 (83.6%) 0.29 363 (84.0%) 160 (82.9%) 0.72 239 (81.0%) 284 (86.1%) 0.089
Confusion 51 (6.5%) 9 (6.1%) 42 (6.6%) 0.82 33 (7.6%) 8 (4.1%) 0.10 21 (7.1%) 20 (6.1%) 0.59
Body temperature
(°C)
37.6 (1.0) 37.4 (0.8) 37.7 (1.0) 0.003 37.9 (0.9) 37.1 (0.9) <0.001 37.6 (0.94) 37.7 (1.02) 0.48
Laboratory values
CRP (mg/l) 173.7 (115.7) 163.3 (112.4) 176.2 (116.4) 0.22 164.9 (111.0) 201.2 (122.2) <0.001 183.7 (121.5) 169.1 (109.9) 0.12
Creatinine (µmol/l) 103.6 (61.3) 114.3 (62.8) 101.0 (60.7) 0.018 103.5 (65.4) 95.7 (49.1) 0.14 106.8 (67.4) 96.1 (54.2) 0.029
Albumin (mg/dl) 31.6 (5.9) 32.3 (5.0) 31.4 (6.1) 0.13 29.9 (5.7) 36.5 (4.8) <0.001 31.5 (5.6) 31.3 (6.7) 0.75
Severity of disease
Total PSI (points) 91.1 (36.7) 92.5 (38.4) 90.8 (36.3) 0.61 94.9 (36.2) 81.4 (34.2) <0.001 91.2 (37.4) 90.3 (35.0) 0.75
PSI class I 92 (11.72%) 18 (12.16%) 74 (11.64%) 39 (9.03%) 33 (17.1%) 39 (13.22%) 33 (10%)
PSI class II 141 (17.96%) 23 (15.54%) 118 (18.55%) 70 (16.2%) 47 (24.35%) 47 (15.93%) 70 (21.21%)
PSI class III 166 (21.15%) 29 (19.59%) 136 (21.38%) 94 (21.76%) 39 (20.21%) 65 (22.03%) 68 (20.61%)
PSI class IV 280 (35.67%) 56 (37.84%) 224 (35.22%) 162 (37.5%) 59 (30.57%) 105 (35.59%) 116 (35.15%)
PSI class 106 (13.5%) 22 (14.86%) 84 (13.21%)
0.86
67 (15.51%) 15 (7.77%)
<0.001
39 (13.22%) 43 (13.03%)
0.42
Initial randomisation
Intervention group
(steroids)
392 (50.0%) 76 (51.4%) 316 (49.7%) 0.72 214 (49.5%) 172 (50.4%) 0.80 147 (49.8%) 163 (49.4%) 0.91
COPD = chronic obstructive pulmonary disease; CRP = C-reactive protein; DRG = diagnosis-related group; PCT = procalcitonin; PSI = Pneumonia Severity Index
Data are mean (standard deviation) or n (%) unless otherwise stated.
* Two hospitals were excluded: one was characterised as a basic hospital, the other was the PCT-enforced centre from analysis A.
† Two of the involved hospitals were excluded (as they had an AP-DRG reimbursement system in place before Swiss DRG was implemented on 1 January 2012).
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based antibiotic stewardship protocol. This was also true
when the analysis was adjusted for important confounders.
In the non-PCT-enforced centres, the PCT algorithm was
known as well, but even if its use was encouraged, its im-
plementation was not emphasised in the same manner. As
adherence to the PCT algorithm was not an endpoint in
the underlying trial, we cannot investigate adherence rates
to the PCT algorithm in individual patients. However, we
know from a previous study, that overall algorithm com-
pliance outside of study conditions was about 90% in the
PCT-enforced centre [48]. Importantly, due to the lack of
patient-level data about the use of PCT in this study, we
can only find an association of PCT-based antibiotic pro-
tocol use and LOS, which does not prove causality. Previ-
ous randomised trials did not find reduced LOS associated
with PCT use. Other clinical pathways, such as discharge
management programmes, that influence LOS may also be
different across centres. As hospitals’ or physicians’ pro-
cess of care were not an endpoint in the underlying trial,
and as there was no censoring of transfers to nurse-led care
wards, to rural (step-down) or to rehabilitation clinics, dir-
ect exploration of these factors is not possible, and we lack
the possibility to further analyse their influence. Also, we
found a significant difference in time to clinical stability
in the PCT-enforced centre compared with other centres,
suggesting a possible unmeasured bias or differences in re-
cording of clinical stability. Still, when this factor was in-
cluded in the regression analysis, results remained robust,
Table 2: Patient outcomes according to use of antibiotic stewardship protocol including procalcitonin.
Outcomes PCT-enforced
(n = 148)
Non-PCT-enforced
(n = 636)
Regression analysis
unadjusted
HR or OR or mean difference
(95% CI)
Regression analysis adjusted
*
HR or OR or mean difference
(95% CI)
Clinical based measures
Time to clinical stability – days† 3.0 (2–3.42) 4.0 (3.5–4.25) HR 1.43 (1.19–1.73), p <0.001 HR 1.41 (1.16–1.70), p <0.001
Total duration of antibiotics – days 8.4 (4.6) 10.2 (5.4) Mean difference 1.80 days
(2.76–0.84), p <0.001
Mean difference 1.85 days
(2.77–0.92), p <0.001
Intravenous antibiotic treatment – days 4.0 (3.1) 6.1 (5.2) Mean difference 2.10 days
(3.0–1.2), p <0.001
Mean difference 2.10 days
(2.96–1.25), p <0.001
Process of care measures (clinical effectiveness)
Death from any cause within 30 days – n (%) 10 (6.76%) 19 (2.99%) OR 2.35 (1.07–5.17), p = 0.033 OR 2.07 (0.84–5.08), p = 0.113
Rehospitalisation – n (%) 7 (4.7%) 53 (8.3%) OR 0.55 (0.24–1.23), p = 0.143 OR 0.52 (0.23–1.20), p = 0.127
CAP-associated complication until day 30 – n
(%)
4 (2.7%) 29 (4.56%) OR 0.58 (0.2–1.68), p = 0.316 OR 0.64 (0.21–1.93), p = 0.428
Process of care measures (economic
effectiveness)
Length of stay – days 5.3 (4.0) 9.2 (8.0) Mean difference 3.92 days
(5.24–2.6), p <0.001
Mean difference 3.92 days
(5.16–2.68), p <0.001
CI = confidence interval; HR = hazard ratio; OR = odds ratio; PCT = procalcitonin
Data are mean (standard deviation) or n (%) unless otherwise stated.
* Adjustment for the following possible confounders: Pneumonia Severity Index; maximal level of C-reactive protein, age, initial randomisation, current smoking status,
presence of chronic obstructive pulmonary disease, diabetes mellitus, cerebrovascular disease, congestive heart failure, malignancy and renal insufficiency.
† Median (interquartile range).
Table 3: Patient outcomes according to type of hospital.
Outcomes University hospitals*
(n = 432)
Non-university
hospitals*
(n = 193)
Regression analysis
unadjusted
HR or OR or mean difference
(95% CI)
Regression analysis adjusted
†
HR or OR or mean difference
(95% CI)
Clinical based measures
Time to clinical stability – days§ 4.42 (4.0–5.0) 2.5 (2.19–3.0) HR 0.57 (0.48–0.68), p <0.001 HR 0.59 (0.5–0.71), p <0.001
Total duration of antibiotics – days 11.0 (5.6) 8.3 (4.0) Mean difference 2.76 days
(1.83–3.69), p <0.001
Mean difference 2.59 days
(1.69–3.49), p <0.001
Intravenous antibiotic treatment – days 6.6 (5.8) 4.9 (3.1) Mean difference 1.69 days
(0.78–2.6), p <0.001
Mean difference 1.35 days
(0.46–2.23), p = 0.003
Process of care measures (clinical effectiveness)
Death from any cause within 30 days – n (%) 16 (3.7%) 1 (0.52%) OR 7.39 (0.97–56.08), p = 0.053 OR 5.54 (0.7–43.9), p = 0.105
Rehospitalisation – n (%) 41 (9.49%) 12 (6.22%) OR 1.58 (0.81–3.08), p = 0.178 OR 1.27 (0.63–2.56), p = 0.501
CAP-associated complication until day 30 – n
(%)
25 (5.79%) 3 (1.55%) OR 3.89 (1.16–13.04), p = 0.028 OR 3.66 (1.06–12.71), p = 0.041
Process of care measures (economic effectiveness)
Length of stay – days 9.9 (8.9) 7.8 (5.1) Mean difference 2.12 days
(0.78–3.46), p = 0.002
Mean difference 1.22 days
(–0.06–2.51), p = 0.061
CI = confidence interval; HR = hazard ratio; OR = odds ratio
Data are mean (standard deviation) or n (%) unless otherwise stated.
* Two hospitals were excluded: one was characterised as a basic hospital; the other was the PCT-enforced centre from analysis A.
† Adjustment for the following possible confounders: Pneumonia Severity Index, maximum level of C-reactive protein, age, initial randomisation, current smoking status,
presence of chronic obstructive pulmonary disease, diabetes mellitus, cerebrovascular disease, congestive heart failure, malignancy and renal insufficiency.
§ Median (interquartile range).
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arguing against such effects being solely responsible for the
observed differences in LOS.
Of note, although in univariate analysis mortality was high-
er in the centre using a PCT-based antibiotic stewardship
protocol, results were no longer statistically significant
after multivariable adjustment, arguing for confounding ef-
fects. In addition, although antibiotic duration in this study
was higher than in previous randomised controlled trials
performed at the same institution (mean 8.4 vs 5.7 in
ProHOSP [25]), the effect was still significant compared
with the other institutions.
We also found some differences in CAP patients treated in
university hospitals compared with non-university hospit-
als. There was a significant difference in total duration of
antibiotic and intravenous antibiotic treatment. These dif-
ferences were robust after adjustment for severity of illness
using the PSI and comorbidities. When adjusted also for
time to clinical stability – as this, too, differed significantly
between university hospitals and non-university hospitals
– the duration of intravenous antibiotic treatment was no
longer significantly different, but the significance in total
duration of antibiotics remained stable. In our study the
type of the institution did not influence LOS.
These findings are largely consistent with the literature,
where variation in quality of care among different types of
hospitals was found as well [2, 16]. As a result of differen-
ces in healthcare systems in different countries and a lack
of standardised classification for hospital types, such com-
parisons may be limited. Most common is the classifica-
tion into major teaching, minor teaching, and nonteaching
hospitals [16, 49–51], or the distinction into regional, rur-
al, and urban/metropolitan hospitals [13, 19, 52]. There is
no consensus regarding quality of care in teaching versus
nonteaching hospitals. No difference in patient outcomes
was found in two reviews from the US comparing teaching
with nonteaching hospitals, and patients from general in-
ternal medicine with mixed (medical and surgical) patients
[50, 51]. An older study from Keeler et al. found that the
quality of care was better in teaching hospitals than in non-
teaching hospitals. However, quality of care was measured
by rating physicians’ performance and more objective cri-
teria such as mortality or LOS were not used [52].
We found significant differences only in the duration of
the antibiotic courses and a trend in regard to LOS. Thus,
our analysis did not reveal big differences in quality of
care between university and non-university hospitals. The
fact that there was no significant difference in the duration
of intravenous antibiotic treatment after also adjusting for
time to clinical stability and bacteraemia emphasises that
patient-based criteria to determine the duration of an in-
travenous treatment are more important than the type of
institution. The longer duration of antibiotic treatment in
university hospitals found in our analysis possibly reflects
the medical education and research activity found at bigger
teaching hospitals, which lead to less effective clinical
pathways and management processes. But as LOS was
not directly influenced, this finding cannot be numbered
among the crucial factors of process of care to increase ef-
ficiency of hospitals.
Summing up the two analyses, we speculate that imple-
mentation of clinical and management pathways in an insti-
tution could help standardise physicians’ practice preferen-
ces, increase efficiency of pathways, and thereby improve
quality of care. But again, prioritised core areas (like a fo-
cus on research or highly specialised medicine) cannot, in-
deed, be obliterated with practice guidelines and optimising
patient processes.
Thirdly, no significant difference in LOS and outcomes
was found in regard to introduction of the DRG system. It
was generally assumed that LOS would be reduced with
the introduction of a DRG-based reimbursement system.
Several studies in various countries have investigated the
effect of a prospective payment system (PPS) such as the
DRG-based reimbursement system on quality of care, but
Table 4: Patient outcomes according to time of implementation of reimbursement based on drug-related groups.
Outcomes Before
implementation of
DRG*
(n = 295)
After implementation
of DRG*
(n = 330)
Regression analysis
unadjusted
HR or OR or mean difference
(95% CI)
Regression analysis adjusted†
HR or OR or mean difference
(95% CI)
Clinical based measures
Time to clinical stability – days§ 3.64 (3.0–4.36) 4 (3.42–4.42) HR 1.07 (0.92–1.26), p = 0.381 HR 1.02 (0.85–1.21), p = 0.871
Total duration of antibiotics – days 10.4 (5.8) 10.0 (4.8) Mean difference 0.40 days
(1.26–(–)0.47), p = 0.37
Mean difference 0.14 days
(0.98–(–)0.71), p = 0.756
Intravenous antibiotic treatment – days 6.2 (5.9) 6.0 (4.5) Mean difference 0.22 days
(1.06–(–)0.62), p = 414
Mean difference –0.08 days
(0.92–(–)0.76), p = 0.857
Process of care measures (clinical effectiveness)
Death from any cause within 30 days – n (%) 9 (3.1%) 8 (2.4%) OR 0.79 (0.30–2.07), p = 0.631 OR 1.14 (0.39–3.36), p = 0.815
Rehospitalisation – n (%) 23 (7.8%) 30 (9.1%) OR 1.18 (0.67–2.09), p = 0.562 OR 1.13 (0.60–2.12), p = 0.701
CAP-associated complication until day 30 – n
(%)
18 (6.1%) 10 (3.03%) OR 0.48 (0.22–1.06), p = 0.069 OR 0.34 (0.13–0.91), p = 0.032
Process of care measures (economic costs)
Length of stay – days 9.7 (8.9) 8.8 (7.0) Mean difference 0.93 days
(2.18–(–)0.33), p = 0.146
Mean difference 0.69 days
(1.92–(–)0.54), p = 0.271
CI = confidence interval; DRG = diagnosis-related group; HR = hazard ratio; OR = odds ratio
Data are mean (standard deviation) or n (%) unless otherwise stated.
* Two of the involved hospitals were excluded as they had an All Patient-DRG reimbursement system in place before SwissDRG was implemented on 1 January 2012.
† Adjustment for the following possible confounders: Pneumonia Severity Index, maximum level of C-reactive protein, age, initial randomisation, current smoking status,
presence of chronic obstructive pulmonary disease, diabetes mellitus, cerebrovascular disease, congestive heart failure, malignancy and renal insufficiency, and for the
treating centre.
§ Median (interquartile range).
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results are controversial. Some studies documented a re-
duction of LOS after implementation of a PPS in the US in
Medicare patients or in patients with hip fractures in a ter-
tiary care setting [53–55]. They revealed that the PPS in-
creased the likelihood that a patient will be discharged in an
unstable condition [54], but no significant long-term effect
on outcomes was documented [55]. In Switzerland a post-
hoc analysis of CAP patients found a significantly shorter
LOS of about 20% in hospitals that used DRG reimburse-
ment systems compared with hospitals using a fee-for-ser-
vice system, without apparent harmful effect on outcomes
[56]. This is also confirmed by a Japanese study focusing
on women with breast cancer, which disclosed a shorter
LOS as well while maintaining the quality of care after im-
plementing DRGs in 2003 [57]. On the other hand, several
studies performed in Germany or in Switzerland observed
no significant change of LOS due to the introduction of G-
DRG or SwissDRG [58, 59], or revealed that the reduction
of LOS was not inevitably connected to the introduction of
DRGs [32, 34]. The lack of effect in the present study may
be explained by the short time period since the implement-
ation of DRGs, as changes in practice need time. In addi-
tion, although the sample size was rather large, it may have
been underpowered to find significant differences.
Our study has important limitations. First, as shown, LOS
is strongly influenced by location-specific and hospital-
specific factors, which makes it difficult to compare with
other regions and healthcare systems. Therefore, our study,
which was embedded in the northern part of Switzerland,
may not be applicable to other regions or countries. Se-
cond, we only included patients with CAP, so that general-
isation to other diagnoses is not possible, and further stud-
ies are required to validate the findings for other medical
problems. Third, as with any observational study, there is
potential residual confounding despite our attempt to adjust
for multiple factors. The study thus shows associations but
does not proof causal effects.
In conclusion, we found differences in LOS associated with
use of an antibiotic stewardship protocol including PCT,
which remained robust after multivariable adjustment,
while the type of hospital and the model of reimbursement
did not influence LOS in our CAP cohort. These data sup-
port the implementation of practice guidelines for in-hos-
pital treatment of CAP patients. More health service re-
search studies are needed to better understand factors as-
sociated with low quality of care and to establish causal
effects.
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Appendix: Sensitivity analysis
Table S1: Fully adjusted regression analysis including time to stability and bacteraemia for all of the patient outcomes measured.
Outcomes A) PCT-enforced vs non-PCT-enforced
Regression analysis fully adjusted HR
or OR or MD (95% CI)*
B) University vs non-university
hospitals†
Regression analysis fully adjusted OR
or MD (95% CI)*
C) Before vs after implementation of
DRG§
Regression analysis fully adjusted OR
or MD (95% CI)*
Clinical based measures
Total duration of antibiotics – days MD 0.97 days (1.75–(–)0.18), p = 0.016 MD 1.47 days (0.69–2.25), p <0.001 MD 0.02 days (0.74–(–)0.70), p = 0.957
Intravenous antibiotic treatment – days MD 1.23 days (1.94–(–)0.52), p = 0.001 MD 0.21 days ((–)0.54–0.95), p = 0.589 MD 0.10 days ((–)0.60–0.80), p = 0.779
Process of care measures (clinical
effectiveness)
Death from any cause within 30 days –
n (%)
OR 2.38 (0.93–6.06), p = 0.07 OR 5.02 (0.62–40.6), p = 0.130 OR 1.27 (0.42–3.89), p = 0.673
Rehospitalisation – n (%) OR 0.65 (0.28–1.52), p = 0.323 OR 0.99 (0.48–2.06), p = 0.995 OR 1.30 (0.68–2.49), p = 0.424
CAP-associated complication until day
30 – n (%)
OR 1.67 (0.50–5.66), p = 0.407 OR 2.78 (0.64–12.06), p = 0.173 OR 0.46 (0.15–1.41), p = 0.174
Process of care measures (economic
costs)
Length of stay – days MD 2.63 days (3.68–(–)1.57), p <0.001 MD 0.35 days (1.46–(–)0.76), p = 0.536 MD 0.39 days (1.44–(–)0.66), p = 0.463
CI = confidence interval; DRG = Diagnosis-Related Group; MD = mean difference; OR = odds ratio; PCT = procalcitonin
Data are mean (standard deviation) or n (%) unless otherwise stated;
* Adjustment for the following possible confounders: Pneumonia Severity Index, maximum level of C-reactive protein, age, initial randomisation, current smoking status,
presence of chronic obstructive pulmonary disease, diabetes mellitus, cerebrovascular disease, congestive heart failure, malignancy and renal insufficiency, as well as
bactaeremia and time to stability.
† Two hospitals were excluded: the first was characterised as a basic hospital, the second was the PCT-enforced hospital from analysis A.
§ Two of the involved hospitals were excluded as they had an All Patient-DRG reimbursement system in place before SwissDRG was implemented on 1 January 2012.
Original article Swiss Med Wkly. 2016;146:w14337
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